Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can require a hospital stay or lead to death. Some people who are high risk for severe illness may be unable to take certain treatments for COVID-19 because they are not available to them, or they take other medicines that may react with a treatment and cause an unwanted effect.

Molnupiravir (MK-4482) is a study medicine designed to stop the COVID-19 virus from copying itself in the body (multiplying). The goal of this study is to learn if molnupiravir prevents severe illness from COVID-19 more than placebo in people who are high risk.

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

Kyiv, Ukraine

Bucharest, Romania

Farmington Hills, MI

Monroe, NC

Charlotte, NC

Georgia Office

Cullman, AL

Orlando, FL

Redmond, WA

Tampa, FL

Miami Lakes, FL

Coral Gables, FL

Miami, FL

Shadow Creek - Pearland, TX

Corpus Christi, TX

Laredo Laguna

Northridge, CA

Los Alamitos, CA

Lima, Peru

Auckland, New Zealand

Pacific Clinical Research Network - Tasman

Merck Sharp & Dohme (MSD)

The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

AstraZeneca

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study.

Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).

COVID-19 sub-study:

The purpose of this research sub-study is to explore the immune response following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination in a subset of subjects on long-term ofatumumab 20 mg sc. Note: Novartis is not supplying the SARS-CoV-2 vaccine.

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Wellesley, MA

Westerville, OH

Northbrook, IL

Raleigh, NC

Office of Clinical Trials

Savannah, GA

Ormond Beach, FL

Clearwater, FL

Hollywood, FL

Bradenton, FL

Pensacola, FL

Port Charlotte, FL

Boulder, CO

Naples, FL

Colorado Springs, CO

Houston, TX

Neuro-Life

Novartis

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC.

This study consists of three sub-studies and a Continuous Treatment Extension (CTE): Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic or due to the geopolitical conflict in Ukraine and surrounding impacted regions. The CTE is an open-label extension for Substudy 3 completers to ensure continuous treatment with risankizumab until such time that risankizumab becomes commercially available and/or the subject can access treatment locally.

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Gastroenterology

Bydgoszcz, Poland

Department of Gastroenterology

Gastroenterology Department

Ematologia Clinical Trials Unit

IdiPAZ - Hemato-Oncologia Pediatrica

Medicina Interna - Ensayos Clinicos

The Helmsley Cancer Center - Oncological Day Hospital

Clinical Research Unit

North Bay, Canada

Mentor, OH

Rheumatology

Optimed Research, LTD

Omaha, NE

Gastrointestinal Research and Clinical Trial Center of Georgia

New Westminster, Canada

Omega Research Orlando, LLC

PerCuro Victoria

New Port Richey, FL

Nagoya City University Hospital

Shreveport, LA

Ophthalmology, Ogden, UT

New Orleans, LA

Tyler, TX

Site Coordinator

Victoria Gastroenterology

San Antonio, TX

UCSF Center for Colitis and Crohn's Disease

Clinical Protocols Department

Smidt Heart Institute

Los Angeles, CA

United Clinical Research - Los Alamitos

JM Research SC

Clinical Research Center - Oncology Department

Centro de Investigacion en Oncologia

Complejo Asistencial Dr. Sotero Del Rio - Investigaciones Medicas SSMSO Office

Cardiology Clinical Trials Unit

Dunedin Hospital - Gastroenterology Research Unit

AbbVie

The study consists of 4 sub-studies, as follows:

* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in participants with moderately to severely active Crohn's disease (CD) who responded to intravenous risankizumab induction treatment in Study M16-006 or Study M15-991;
* Sub-study 2 (Randomized, exploratory maintenance study) to evaluate the efficacy and safety of two different dosing regimens for risankizumab as maintenance therapy in participants who responded to induction treatment in Study M16-006 or Study M15-991;
* Sub-study 3 (Open-label, long-term extension study) to evaluate long-term safety of risankizumab in participants who completed Sub-study 1, Sub-study 2, another AbbVie risankizumab Crohn's disease study, or participants who responded to induction treatment in Study M16-006 or Study M15-991 with no final endoscopy due to the Covid-19 pandemic. Additional objectives are to further investigate long-term efficacy and tolerability of risankizumab;
* Sub-study 4 (Open-label On Body Injector (OBI) administration and long-term extension study) to evaluate patient-reported outcomes, efficacy, safety, tolerability, and pharmacokinetics of risankizumab administered via OBI in participants who are receiving maintenance treatment with risankizumab.
* OL CTE to ensure uninterrupted care in accordance with local regulations until risankizumab is commercially available for participants who completed Sub-study 3, Sub-study 4.

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Find clinical trials for COVID-19 in Warszawa, Mazowieckie

Related conditions:

COVID-19 trials near Warszawa, Mazowieckie, POL:

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (MOVe-NOW)

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA)

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS)

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis (COMMAND)

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease (FORTIFY)

Find clinical trials for COVID-19 in .css-epvm6{white-space:nowrap;}Warszawa, Mazowieckie